EBV Latency Types Adopt Alternative Chromatin Conformations
Epstein-Barr Virus (EBV) can establish latent infections with distinct gene expression patterns referred to as latency types. These different latency types are epigenetically stable and correspond to different promoter utilization. Here we explore the three-dimensional conformations of the EBV genome in different latency types. We employed Chromosome Conformation Capture (3C) assay to investigate chromatin loop formation between the OriP enhancer and the promoters that determine type I (Qp) or type III (Cp) gene expression. We show that OriP is in close physical proximity to Qp in type I latency, and to Cp in type III latency. The cellular chromatin insulator and boundary factor CTCF was implicated in EBV chromatin loop formation. Combining 3C and ChIP assays we found that CTCF is physically associated with OriP-Qp loop formation in type I and OriP-Cp loop formation in type III latency. Mutations in the CTCF binding site located at Qp disrupt loop formation between Qp and OriP, and lead to the activation of Cp transcription. Mutation of the CTCF binding site at Cp, as well as siRNA depletion of CTCF eliminates both OriP-associated loops, indicating that CTCF plays an integral role in loop formation. These data indicate that epigenetically stable EBV latency types adopt distinct chromatin architectures that depend on CTCF and mediate alternative promoter targeting by the OriP enhancer.
Vyšlo v časopise:
EBV Latency Types Adopt Alternative Chromatin Conformations. PLoS Pathog 7(7): e32767. doi:10.1371/journal.ppat.1002180
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1002180
Souhrn
Epstein-Barr Virus (EBV) can establish latent infections with distinct gene expression patterns referred to as latency types. These different latency types are epigenetically stable and correspond to different promoter utilization. Here we explore the three-dimensional conformations of the EBV genome in different latency types. We employed Chromosome Conformation Capture (3C) assay to investigate chromatin loop formation between the OriP enhancer and the promoters that determine type I (Qp) or type III (Cp) gene expression. We show that OriP is in close physical proximity to Qp in type I latency, and to Cp in type III latency. The cellular chromatin insulator and boundary factor CTCF was implicated in EBV chromatin loop formation. Combining 3C and ChIP assays we found that CTCF is physically associated with OriP-Qp loop formation in type I and OriP-Cp loop formation in type III latency. Mutations in the CTCF binding site located at Qp disrupt loop formation between Qp and OriP, and lead to the activation of Cp transcription. Mutation of the CTCF binding site at Cp, as well as siRNA depletion of CTCF eliminates both OriP-associated loops, indicating that CTCF plays an integral role in loop formation. These data indicate that epigenetically stable EBV latency types adopt distinct chromatin architectures that depend on CTCF and mediate alternative promoter targeting by the OriP enhancer.
Zdroje
1. KieffE 2007 Epstein-Barr Virus and its replication.; FieldsBNKnipeDMHowleyPM Philadelphia Wolters Kluwer Health/Lippincott Williams & Wilkins 2 v. (xix, 3091, 3086 p.)
2. RickinsonABKieffE 2007 Epstein-Barr Virus.; FieldsBNKnipeDMHowleyPM Philadelphia Wolters Kluwer Health/Lippincott Williams & Wilkins 2 v. (xix, 3091, 3086 p.)
3. YoungLSRickinsonAB 2004 Epstein-Barr virus: 40 years on. Nat Rev Cancer 4 757 768
4. RoweMLearALCroom-CarterDDaviesAHRickinsonAB 1992 Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66 122 131
5. MiyashitaEMYangBLamKMCrawfordDHThorley-LawsonDA 1995 A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80 593 601
6. BabcockGJDeckerLLVolkMThorley-LawsonDA 1998 EBV persistence in memory B cells in vivo. Immunity 9 395 404
7. BabcockGJHochbergDThorley-LawsonAD 2000 The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13 497 506
8. KellyGBellARickinsonA 2002 Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8 1098 1104
9. QuLRoweDT 1992 Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 66 3715 3724
10. TierneyRJStevenNYoungLSRickinsonAB 1994 Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68 7374 7385
11. ShibataDWeissLM 1992 Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 140 769 774
12. Raab-TraubN 2002 Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12 431 441
13. FahraeusRFuHLErnbergIFinkeJRoweM 1988 Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42 329 338
14. GilliganKSatoHRajaduraiPBussonPYoungL 1990 Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. J Virol 64 4948 4956
15. YoungLSDawsonCWClarkDRupaniHBussonP 1988 Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69 Pt 5 1051 1065
16. ImaiSKoizumiSSugiuraMTokunagaMUemuraY 1994 Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A 91 9131 9135
17. NiedobitekGHansmannMLHerbstHYoungLSDienemannD 1991 Epstein-Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. J Pathol 165 17 24
18. PallesenGHamilton-DutoitSJRoweMYoungLS 1991 Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337 320 322
19. ChiangAKTaoQSrivastavaGHoFC 1996 Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 68 285 290
20. FarrellPJ 1995 Epstein-Barr virus immortalizing genes. Trends Microbiol 3 105 109
21. MinarovitsJ 2006 Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol 310 61 80
22. SchaeferBCStromingerJLSpeckSH 1995 Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci U S A 92 10565 10569
23. WoisetschlaegerMJinXWYandavaCNFurmanskiLAStromingerJL 1991 Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc Natl Acad Sci U S A 88 3942 3946
24. WoisetschlaegerMYandavaCNFurmanskiLAStromingerJLSpeckSH 1990 Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc Natl Acad Sci U S A 87 1725 1729
25. NonkweloCSkinnerJBellARickinsonASampleJ 1996 Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 70 623 627
26. BodescotMPerricaudetMFarrellPJ 1987 A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol 61 3424 3430
27. TierneyRNagraJHutchingsIShannon-LoweCAltmannM 2007 Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. J Virol 81 10092 10100
28. AltmannMPichDRuissRWangJSugdenB 2006 Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc Natl Acad Sci U S A 103 14188 14193
29. ReismanDSugdenB 1986 trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol 5 3838 3846
30. PuglielliMTWoisetschlaegerMSpeckSH 1996 oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol 70 5758 5768
31. YoshiokaMCrumMMSampleJT 2008 Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing. J Virol 82 1679 1687
32. TakacsMSalamonDMyohanenSLiHSegesdiJ 2001 Epigenetics of latent Epstein-Barr virus genomes: high resolution methylation analysis of the bidirectional promoter region of latent membrane protein 1 and 2B genes. Biol Chem 382 699 705
33. TemperaILiebermanPM 2010 Chromatin organization of gammaherpesvirus latent genomes. Biochim Biophys Acta 1799 236 245
34. AmbinderRFRobertsonKDTaoQ 1999 DNA methylation and the Epstein-Barr virus. Semin Cancer Biol 9 369 375
35. DayLChauCMNebozhynMRennenkampAJShoweM 2007 Chromatin Profiling Of Epstein-Barr Virus Latency Control Region. J Virol 81 6389 401
36. RobertsonKDMannsASwinnenLJZongJCGulleyML 1996 CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood 88 3129 3136
37. TemperaIWiedmerADheekolluJLiebermanPM 2010 CTCF prevents the epigenetic drift of EBV latency promoter Qp. PLoS Pathog 6 e1001048
38. GurudattaBVCorcesVG 2009 Chromatin insulators: lessons from the fly. Brief Funct Genomic Proteomic 8 276 282
39. BusheyAMDormanERCorcesVG 2008 Chromatin insulators: regulatory mechanisms and epigenetic inheritance. Mol Cell 32 1 9
40. LanctotCCheutinTCremerMCavalliGCremerT 2007 Dynamic genome architecture in the nuclear space: regulation of gene expression in three dimensions. Nat Rev Genet 8 104 115
41. DekkerJRippeKDekkerMKlecknerN 2002 Capturing chromosome conformation. Science 295 1306 1311
42. FraserPBickmoreW 2007 Nuclear organization of the genome and the potential for gene regulation. Nature 447 413 417
43. SextonTSchoberHFraserPGasserSM 2007 Gene regulation through nuclear organization. Nat Struct Mol Biol 14 1049 1055
44. KageyMHNewmanJJBilodeauSZhanYOrlandoDA 2010 Mediator and cohesin connect gene expression and chromatin architecture. Nature 467 430 5
45. LingJQLiTHuJFVuTHChenHL 2006 CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. Science 312 269 272
46. PhillipsJECorcesVG 2009 CTCF: master weaver of the genome. Cell 137 1194 1211
47. OhlssonRRenkawitzRLobanenkovV 2001 CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 17 520 527
48. OhlssonRLobanenkovVKlenovaE 2010 Does CTCF mediate between nuclear organization and gene expression? Bioessays 32 37 50
49. MajumderPBossJM 2010 CTCF controls expression and chromatin architecture of the human major histocompatibility complex class II locus. Mol Cell Biol 30 4211 4223
50. SplinterEHeathHKoorenJPalstraRJKlousP 2006 CTCF mediates long-range chromatin looping and local histone modification in the beta-globin locus. Genes Dev 20 2349 2354
51. FilippovaGNFagerlieSKlenovaEMMyersCDehnerY 1996 An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 16 2802 2813
52. LobanenkovVVNicolasRHAdlerVVPatersonHKlenovaEM 1990 A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5′-flanking sequence of the chicken c-myc gene. Oncogene 5 1743 1753
53. KlenovaEMNicolasRHPatersonHFCarneAFHeathCM 1993 CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms. Mol Cell Biol 13 7612 7624
54. ChauCMZhangXYMcMahonSBLiebermanPM 2006 Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF. J Virol 80 5723 5732
55. DekkerJ 2006 The three ‘C' s of chromosome conformation capture: controls, controls, controls. Nat Methods 3 17 21
56. DengZLezinaLChenCJShtivelbandSSoW 2002 Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication. Mol Cell 9 493 503
57. DengZAtanasiuCBurgJSBroccoliDLiebermanPM 2003 Telomere repeat binding factors TRF1, TRF2, and hRAP1 modulate replication of Epstein-Barr virus OriP. J Virol 77 11992 12001
58. PaulsonEJFingerothJDYatesJLSpeckSH 2002 Methylation of the EBV genome and establishment of restricted latency in low-passage EBV-infected 293 epithelial cells. Virology 299 109 121
59. AlazardNGruffatHHiriartESergeantAManetE 2003 Differential hyperacetylation of histones H3 and H4 upon promoter-specific recruitment of EBNA2 in Epstein-Barr virus chromatin. J Virol 77 8166 8172
60. AtanasiuCDengZWiedmerANorseenJLiebermanPM 2006 ORC binding to TRF2 stimulates OriP replication. EMBO Rep 7 716 721
61. MackeyDMiddletonTSugdenB 1995 Multiple regions within EBNA1 can link DNAs. J Virol 69 6199 6208
62. MiddletonTSugdenB 1992 EBNA1 can link the enhancer element to the initiator element of the Epstein-Barr virus plasmid origin of DNA replication. J Virol 66 489 495
63. FrappierLO'DonnellM 1991 Overproduction, purification, and characterization of EBNA1, the origin binding protein of Epstein-Barr virus. J Biol Chem 266 7819 7826
64. GahnTASugdenB 1995 An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Esptein-Barr virus LMP Gene. J Virol 69 2633 2636
65. WysokenskiDAYatesJL 1989 Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus. J Virol 63 2657 2666
66. PaulsonEJSpeckSH 1999 Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals. J Virol 73 9959 9968
67. ErnbergIFalkKMinarovitsJBussonPTurszT 1989 The role of methylation in the phenotype modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J gen Virol 70 2989 3002
68. YuWGinjalaVPantVChernukhinIWhiteheadJ 2004 Poly(ADP-ribosyl)ation regulates CTCF-dependent chromatin insulation. Nat Genet 36 1105 1110
69. El-KadyAKlenovaE 2005 Regulation of the transcription factor, CTCF, by phosphorylation with protein kinase CK2. FEBS Lett 579 1424 1434
70. MacphersonMJBeattyLGZhouWDuMSadowskiPD 2008 The CTCF insulator protein is post-translationally modified by SUMO. Mol Cell Biol
71. HagegeHKlousPBraemCSplinterEDekkerJ 2007 Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat Protoc 2 1722 1733
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2011 Číslo 7
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
Najčítanejšie v tomto čísle
- Requires Glycerol for Maximum Fitness During The Tick Phase of the Enzootic Cycle
- Comparative Genomics Yields Insights into Niche Adaptation of Plant Vascular Wilt Pathogens
- “Persisters”: Survival at the Cellular Level
- The Role of IL-15 Deficiency in the Pathogenesis of Virus-Induced Asthma Exacerbations